Haemophilus influenzae type B (HiB) VACCINE

Menhibrix, a new 4-dose combination vaccine to protect against meningococcal and Hib diseases, has been approved for use in ages 6 weeks to 18 months. Link to FDA News Release (6-14-12)
Hiberix, a vaccine against Haemophilus influenzae type b (Hib), has been approved by the US FDA as a booster dose. The vaccine was approved through an accelerated process to ease the shortage of Hib vaccine in the US. Link to FDA News Release (Aug 19 09)
Continued Shortage of Haemophilus influenzae Type b (Hib) Conjugate Vaccines and Potential Implications for Hib Surveillance --- United States, 2008. MMWR Nov 21 2008:57(46);1252-5. [Dec 08]
- no increase in disease due to shortage
IVS has learned that no samples of the recalled lots were found to be contaminated. [Dec 08]
Pentacel, a vaccine for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease caused by Haemophilus influenzae type b for infants and children 6 weeks through 4 years of age (prior to fifth birthday), was approved by the US FDA in June 2008.

This page was last updated on November 07, 2012